Kwa Andrea, Kasiakou Sofia K, Tam Vincent H, Falagas Matthew E
Singapore General Hospital, Outram Road, 169608, Singapore.
Expert Rev Anti Infect Ther. 2007 Oct;5(5):811-21. doi: 10.1586/14787210.5.5.811.
Hospital-acquired infections due to multidrug-resistant gram-negative bacteria constitute major health problems, since the medical community is continuously running out of available effective antibiotics and no new agents are in the pipeline. Polymyxins, a group of antibacterials that were discovered during the late 1940s, represent some of the last treatment options for these infections. Only two polymyxins are available commercially, polymyxin E (colistin) and polymyxin B. Although several reviews have been published recently regarding colistin, no review has focused on the similarities and differences between polymyxin B and colistin. These two medications have many similarities with respect to mechanism of action, antimicrobial spectrum, clinical uses and toxicity. However, they also differ in several aspects, including chemical structure, formulation, potency, dosage and pharmacokinetic properties.
由多重耐药革兰氏阴性菌引起的医院获得性感染构成了重大的健康问题,因为医学界可用的有效抗生素不断短缺,且尚无新的药物正在研发中。多粘菌素是在20世纪40年代末发现的一类抗菌药物,是这些感染的一些最后的治疗选择。市面上仅有两种多粘菌素可供使用,即多粘菌素E(黏菌素)和多粘菌素B。尽管最近发表了几篇关于黏菌素的综述,但尚无综述聚焦于多粘菌素B和黏菌素之间的异同。这两种药物在作用机制、抗菌谱、临床用途和毒性方面有许多相似之处。然而,它们在几个方面也存在差异,包括化学结构、剂型、效力、剂量和药代动力学特性。